Finally, we found that siringin can block the interaction between PR-DPR and component 1 Q subcomponent-binding protein (C1QBP), which may be used for therapeutic intervention in C9-ALS in the future. This evidence concerns the gene C1QBP and amyotrophic lateral sclerosis.